HK Stock Market Move | IMMUNEONCO-B(01541) up by more than 10%, IMM0306 approved for Phase II clinical trial in the treatment of primary membranous nephropathy

IMMUNEONCO-B (01541) surged by more than 10%, as of the time of writing, it rose by 10.46% to 5.28 Hong Kong dollars, with a turnover of 7.0334 million Hong Kong dollars. On the news front, on March 17th, Imunonco announced that its independently developed drug, Amourivop (IMM0306), for the treatment of Primary Membranous Nephropathy (PMN) has officially obtained approval for Phase II clinical trials from the National Medical Products Administration (NMPA). This is another major milestone for IMM0306 in the field of autoimmune kidney diseases, marking a substantial step towards the treatment of kidney diseases with this innovative drug. The company stated that the approval of Phase II clinical trials for IMM0306 in the treatment of Primary Membranous Nephropathy (PMN), along with the recent approval of the subcutaneous injection formulation of Amourivop (IMM0306S), represents the latest achievement in Imunonco's intensive deployment in the field of autoimmune diseases, and is also a significant manifestation of the company's "multiple breakthroughs in the self-immune pipeline" strategy.